Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Kintara Therapeutics Inc (KTRA)

Kintara Therapeutics Inc (KTRA)
0.2154 -0.0145 (-6.31%) 10/18/24 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Thu, Oct 17th, 2024
Day Low
0.2049
Day High
0.2356
Open 0.2356
Previous Close 0.2299 0.2299
Volume 3,700,200 3,700,200
Avg Vol 5,464,335 5,464,335
Stochastic %K 77.09% 77.09%
Weighted Alpha -52.80 -52.80
5-Day Change +0.0392 (+22.25%) +0.0392 (+22.25%)
52-Week Range 0.0810 - 4.5861 0.0810 - 4.5861
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,913
  • Shares Outstanding, K 55,305
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,320 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.12
  • Most Recent Earnings $-0.05 on 05/14/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1580 +36.33%
on 09/20/24
Period Open: 0.1911
0.2399 -10.21%
on 10/15/24
+0.0243 (+12.72%)
since 09/17/24
3-Month
0.1553 +38.70%
on 09/12/24
Period Open: 0.2717
0.2839 -24.13%
on 07/18/24
-0.0563 (-20.72%)
since 07/17/24
52-Week
0.0810 +165.93%
on 03/12/24
Period Open: 3.7200
4.5861 -95.30%
on 10/19/23
-3.5046 (-94.21%)
since 10/17/23

Most Recent Stories

More News
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 76.46 (-2.46%)
NVS : 109.58 (-0.32%)
RHHBY : 38.5800 (+0.21%)
AZN : 67.05 (-1.21%)
BMRN : 58.82 (-2.00%)
KTRA : 0.2154 (-6.31%)
XBIT : 2.96 (-6.92%)
RKV.VN : 0.045 (-10.00%)
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the Emerging Growth Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the Aegis Capital Virtual Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.2154 (-6.31%)
Is Kintara Therapeutics A Hidden Gem?

Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.

KTRA : 0.2154 (-6.31%)
Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Kintara Therapeutics, Inc. (NASDAQ: KTRA) is engaged as a biopharmaceutical company, which is focused on the research and development of

KTRA : 0.2154 (-6.31%)

Business Summary

Kintara Therapeutics Inc. is a biopharmaceutical company. It is focused on the development of new solid tumor cancer therapies. The company's program includes VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer, which are in clinical stage. Kintara Therapeutics Inc. is based in San Diego,...

See More

Key Turning Points

3rd Resistance Point 0.2631
2nd Resistance Point 0.2493
1st Resistance Point 0.2324
Last Price 0.2154
1st Support Level 0.2017
2nd Support Level 0.1879
3rd Support Level 0.1710

See More

52-Week High 4.5861
Fibonacci 61.8% 2.8652
Fibonacci 50% 2.3335
Fibonacci 38.2% 1.8019
Last Price 0.2154
52-Week Low 0.0810

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro